1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

This report gives you a new and unique way of stratifying and analyzing the global melanoma pipeline and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets and companies are setting the path?
* What is first-in-class in the melanoma pipeline?
* Is First-in-Class the Best-in-Class?
* Indication expansion opportunities
* Drug repositioning opportunities
* Which pathways are targeted, by what and how?
* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 282 melanoma drugs from within the portfolio of 164 companies world-wide, from Ceased to Marketed. We have identified 226 drug targets, which we have organized into 187 drug target strategies and assessed them in melanoma.

Our pipeline analysis has five levels:

1. Target Atlas: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2. First-in-Class to Best-in-Class: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.

4. Indication Selection: Shows the distribution and deployment of target strategies in melanoma.

5. Competive Landscape: Provides a cross-examination of each company’s entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:
* Head-to-head target competing analysis

* Significant drug target overlap analysis

* Cross-sectional R&D profiling of individual drug targets.

* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company’s pipeline:
-Where are we?
- Where is our general and specific competition?
- What is the level of competition where we want to be?

* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company’s interest in the melanoma pipeline by:

* Better identifying benchmarking peers

* Providing rationale for in/out licensing decisions of drug candidates

* Performing proper drug due diligence

* Strategies for commercial planning

* Guiding Research & Development efforts

Table Of Contents

Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?
1 Executive Summary 3

2 About Cancer Highlights - A Module of the DevOnc Platform 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group's Oncology Team 6

3 Methodology 7
3.1 Cancer Highlights' Five Pillar Drug Assessment 7

4 Table of Contents 9
4.1 List of Figures 19
4.2 List of Tables 19

5 Introduction 26
5.1 The Scope of this Report 26
5.2 Definitions 29
5.3 Abbreviations 29

6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment 30
6.1 Drug Repositioning in Oncology 30
6.2 Introduction to Targets of Melanoma Drugs 31
6.2.1 Carboxy-lyase Activity Targets 39
6.2.2 Carboxypeptidase Activity Targets 40
6.2.3 Catalytic Activity Targets 42
6.2.4 Cell Adhesion Molecule Activity Targets 49
6.2.5 Chaperone Activity Targets 55
6.2.6 Chemokine Activity Targets 63
6.2.7 Cofactor Binding Targets 65
6.2.8 Cysteine-type Peptidase Activity Targets 67
6.2.9 Cytokine Activity Targets 69
6.2.10 DNA Binding Targets 81
6.2.11 DNA Repair Protein Targets 82
6.2.12 DNA Topoisomerase Activity Targets 84
6.2.13 DNA-directed DNA Polymerase Activity Targets 87
6.2.14 DNA-methyltransferase Activity Targets 92
6.2.15 Extracellular Ligand-gated Ion Channel Activity Targets 93
6.2.16 Extracellular Matrix Structural Constituent Targets 94
6.2.17 G-protein Coupled Receptor Activity Targets 98
6.2.18 Growth Factor Activity Targets 108
6.2.19 GTPase Activity Targets 115
6.2.20 Hydrolase Activity Targets 116
6.2.21 Isomerase Activity Targets 117
6.2.22 Kinase Activity Targets 120
6.2.23 Kinase Binding Targets 131
6.2.24 Kinase Regulator Activity Targets 134
6.2.25 Ligase Activity Targets 135
6.2.26 Lipase Activity Targets 140
6.2.27 Lipid Kinase Activity Targets 141
6.2.28 Metallopeptidase Activity Targets 152
6.2.29 MHC Class I Receptor Activity Targets 154
6.2.30 Molecular Function Unknown Targets 155
6.2.31 Motor Activity Targets 167
6.2.32 Oxidoreductase Activity Targets 169
6.2.33 Peptide Hormone Targets 174
6.2.34 Protein Binding Targets 175
6.2.35 Protein Serine/Threonine Kinase Activity Targets 179
6.2.36 Protein Threonine/Tyrosine Kinase Activity Targets 214
6.2.37 Protein Tyrosine Phosphatase Activity Targets 219
6.2.38 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 226
6.2.39 Protein-tyrosine Kinase Activity Targets 227
6.2.40 Receptor Activity Targets 240
6.2.41 Receptor Binding Targets 270
6.2.42 Receptor Signaling Complex Scaffold Activity Targets 275
6.2.43 RNA Binding Targets 278
6.2.44 RNA-directed DNA Polymerase Activity Targets 279
6.2.45 Serine-type Peptidase Activity Targets 280
6.2.46 Structural Constituent of Cytoskeleton Targets 282
6.2.47 Superoxide Dismutase Activity Targets 284
6.2.48 T Cell Receptor Activity Targets 288
6.2.49 Transcription Factor Activity Targets 293
6.2.50 Transcription Regulator Activity Targets 306
6.2.51 Transferase Activity Targets 310
6.2.52 Translation Regulator Activity Targets 311
6.2.53 Transmembrane Receptor Activity Targets 313
6.2.54 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 321
6.2.55 Transporter Activity Targets 361
6.2.56 Ubiquitin-specific Protease Activity Targets 363
6.2.57 Unknown Targets 364
6.2.58 Voltage-gated Ion Channel Activity Targets 365
6.2.59 Other Targets 366
6.3 Mutation Profiles of Melanoma Drug Targets 369
6.3.1 Targets of Melanoma Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 369
6.4 Target-Target Interactions among Identified Targets of Melanoma Drugs 376
6.5 Protein Expression Levels of Identified Targets of Melanoma Drugs 380
6.6 The Drug-Target Competitive Landscape 383
6.7 Pathway Assessment of Melanoma Drugs 387
6.7.1 Tools for Analysis of Cancer Pathways 388
6.7.2 Pathway Assessment 389

7 First-in-Class and Me-too Analysis of Melanoma Drugs 468
7.1 First-in-Class and Me-too Drugs in Pe-registration and Marketed 471
7.2 First-in-Class and Me-too in Phase III Clinical Development 472
7.3 First-in-Class and Me-too in Phase II Clinical Development 474
7.4 First-in-Class and Me-too in Phase I Clinical Development 479
7.5 First-in-Class and Me-too in Preclinical Development 483
7.6 Drug Target Strategies of No Data, Suspended or Terminated Melanoma Drugs 485

8 Is First-in-Class the Best-in-Class? 488
8.1.1 Marketed 491
8.1.2 Pre-registration 497
8.1.3 Phase III 498
8.1.4 Phase II 508
8.1.5 Phase I 574
8.1.6 Preclinical 617
8.1.7 No Data 638
8.1.8 Suspended 639
8.1.9 Ceased 642

9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy 679
9.1 Small Molecules 681
9.1.1 Background 681
9.1.2 Target Strategies of Small Molecule Drugs 682
9.2 Peptide and Protein Drugs 691
9.2.1 Background 691
9.2.2 Target Strategies of Peptide and Protein Drugs 692
9.3 Antibodies 698
9.3.1 Background 698
9.3.2 Target Strategies of Antibody Drugs 698
9.4 Nucleic Acid Therapies 701
9.4.1 Background 701
9.4.2 Target Strategies of Nucleic Acid Drugs 702
9.5 Cell and Gene Therapy 704
9.5.1 Background 704
9.5.2 Target Strategies of Cell and Gene Therapy Drugs 705
9.6 Drug Delivery and Nanotechnology 709
9.6.1 Background 709
9.6.2 Target Strategies of Reformulated Drugs 709

10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711

11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company 716
11.1 Changes in the Competitive Landscape: MandA, Bankruptcy and Name Change 720
11.2 Company Facts and Ranking 722
11.3 Competitive Fall-Out Assessment 729
11.4 3SBio 731
11.5 AB Science 734
11.6 Abbott 736
11.7 AbbVie 739
11.8 Abiogen 742
11.9 Actelion 744
11.10 Adherex 746
11.11 Advanced Life Sciences 748
11.12 Agenus 750
11.13 Alnylam 752
11.14 AlphaVax 754
11.15 Altor BioScience 756
11.16 Ambit Biosciences 759
11.17 Amgen 762
11.18 AngioChem 766
11.19 Antisense Pharma 769
11.20 Antisoma 771
11.21 Aphios 773
11.22 ApopLogic Pharmaceuticals 775
11.23 Apotex 777
11.24 Ariad 779
11.25 ArQule 781
11.26 Array BioPharma 784
11.27 Astellas 788
11.28 Astex Pharmaceuticals 792
11.29 AstraZeneca 796
11.30 Attenuon 800
11.31 Bayer 802
11.32 Bio-Medisinsk Innovasjon 807
11.33 BioAlliance Pharma 809
11.34 Biogen Idec 811
11.35 Biokine Therapeutics 814
11.36 BioNTech 816
11.37 BioNumerik 818
11.38 BioSante 820
11.39 Biosceptre 823
11.40 Biotech Ltd 825
11.41 Biotecnol 828
11.42 BioVex 831
11.43 Boehringer Ingelheim 833
11.44 Bristol-Myers Squibb 835
11.45 Cancer Research Technology 843
11.46 CDG Therapeutics 845
11.47 Celgene 847
11.48 Celldex Therapeutics 850
11.49 Celtic Pharma 852
11.50 CJ Corp 855
11.51 Clavis Pharma 858
11.52 Cosmo Pharmaceuticals 860
11.53 CSL 862
11.54 CureTech 864
11.55 CytImmune Sciences 866
11.56 Cytokinetics 868
11.57 Daewoong 870
11.58 Daiichi Sankyo 872
11.59 Dara Biosciences 877
11.60 Deciphera Pharmaceuticals 879
11.61 DNAVEC 882
11.62 Dong-A 884
11.63 Eisai 888
11.64 Eli Lilly 893
11.65 EntreMed 898
11.66 Enzon 902
11.67 EpiCept 905
11.68 Exelixis 909
11.69 Flamel Technologies 914
11.70 Genmab 917
11.71 Genta 919
11.72 GenVec 921
11.73 Geron 923
11.74 GlaxoSmithKline 925
11.75 Gradalis 930
11.76 Hemispherx Biopharma 932
11.77 Hoffmann-La Roche 934
11.78 Ichor Medical Systems 943
11.79 Idera Pharmaceuticals 945
11.80 Immunocore 947
11.81 ImmunoGen 951
11.82 Immunovaccine 953
11.83 ImmuPharma 955
11.84 Incyte Corporation 957
11.85 Infinity Pharmaceuticals 959
11.86 Innate Pharma 962
11.87 Inotek 964
11.88 Inovio 967
11.89 Intas Biopharmaceuticals 969
11.90 Intracel 972
11.91 Intrexon 974
11.92 Introgen Therapeutics 976
11.93 Ipsen 978
11.94 Jennerex Biotherapeutics 980
11.95 Johnson and Johnson 982
11.96 KAEL-GemVax 985
11.97 Kalypsys 987
11.98 Karyon-CTT 990
11.99 Kiadis 992
11.100 Leo 994
11.101 LG Life Sciences 996
11.102 Ligand 999
11.103 Lipotek 1001
11.104 Mannkind 1003
11.105 Meda 1005
11.106 MediGene 1007
11.107 Medisyn Technologies 1011
11.108 Merck and Co 1013
11.109 Merck KGaA 1016
11.110 Mitsubishi Tanabe Pharma 1019
11.111 Mochida 1021
11.112 Mojave Therapeutics 1024
11.113 MolMed 1026
11.114 Mologen 1028
11.115 Nereus Pharmaceuticals 1030
11.116 Non-industrial source 1032
11.117 Novartis 1034
11.118 Novogen 1044
11.119 Oasmia 1046
11.120 Oncalis 1049
11.121 Oncovir 1051
11.122 Oxford BioMedica 1053
11.123 Pacific Biotech 1055
11.124 Patrys 1057
11.125 PBL Therapeutics 1059
11.126 Pfizer 1062
11.127 PharmaMar 1068
11.128 PhiloGene 1072
11.129 Pierre Fabre 1074
11.130 Piramal 1077
11.131 Progen 1079
11.132 Reata Pharmaceuticals 1081
11.133 Regulon 1083
11.134 Reliance Life Sciences 1085
11.135 Rexahn 1088
11.136 Sanofi 1090
11.137 Santaris Pharma 1094
11.138 Santhera Pharmaceuticals 1096
11.139 Sareum 1099
11.140 Scancell 1102
11.141 Seattle Genetics 1104
11.142 Shire 1106
11.143 Simcere Pharmaceuticals 1108
11.144 Solbec Pharmaceuticals 1110
11.145 Spirogen 1112
11.146 Sunesis 1114
11.147 Swedish Orphan Biovitrum 1116
11.148 Synta Pharmaceuticals 1119
11.149 Takeda 1122
11.150 Tapestry Pharmaceuticals 1126
11.151 Targa Therapeutics 1129
11.152 Targepeutics 1131
11.153 Tau Therapeutics 1133
11.154 Thallion Pharmaceuticals 1135
11.155 Therion Biologics 1137
11.156 to-BBB 1139
11.157 Tolerx 1141
11.158 TopoTarget 1143
11.159 Tracon Pharmaceuticals 1145
11.160 Transgene 1147
11.161 VBL Therapeutics 1149
11.162 Vectura 1151
11.163 Vical 1153
11.164 VioQuest 1157
11.165 WntResearch 1159
11.166 Xerion 1161
11.167 York Pharma 1164

12 Disclaimer 1166

13 Drug Index 1167

14 Company Index 1175



List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Melanoma Drugs 379
Figure 2: The Drug-Target Competitive Landscape of Melanoma Drugs - Large Cluster 384
Figure 3: The Drug-Target Competitive Landscape Melanoma Drugs - Smaller Clusters 385
Figure 4: Head-to-Head Targeting Competitive Landscape of Melanoma Drugs 386
Figure 5: Number of Companies per Ranking Level 724



List of Tables

Table 1: Cancer Highlights' Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Melanoma Drug Pipeline by Stage of Development 26
Table 3: Head to Head Target Competition among Melanoma Drugs 26
Table 4: Overview of Drug Target Strategy Themes 31
Table 5: Ceased Targets of Melanoma Drugs 32
Table 6: Official Gene Symbol to Target Profle 33
Table 7: Mutation Frequencies of Melanoma Drug Targets 370
Table 8: Number of Target-Target Interactions among Targets of Melanoma Drugs 377
Table 9: Available Protein Expression Profiles of Melanoma Drug Targets 380
Table 10: Pathway Summary 389
Table 11: Drug Targets without any Identified Assigned Pathways 389
Table 12: Pathway Profiles According to BioCarta of Melanoma Drug Targets 391
Table 13: Pathway Profiles According to KEGG of Melanoma Drug Targets 416
Table 14: Pathway Profiles According to NetPath of Melanoma Drug Targets 455
Table 15: First-in-Class Analysis of Drug Target Strategies 469
Table 16: Top Competitive Target Strategies of Melanoma Drugs 469
Table 17: First-in-Class and Me-too of Melanoma Drugs in Pre-registration or being Marketed 471
Table 18: The Competition Through Close Mechanistic Approximation Between Drugs being Marketing for the Treatment of Melanoma 471
Table 19: First-in-Class and Me-too of Melanoma Drugs in Phase III Clinical 472
Table 20: The Competition Through Close Mechanistic Approximation Between Phase III Melanoma Drugs 473
Table 21: First-in-Class and Me-too of Melanoma Drugs in Phase II Clinical Development 474
Table 22: The Competition Through Close Mechanistic Approximation Between Phase II Melanoma Drugs 477
Table 23: First-in-Class and Me-too of Melanoma Drugs in Phase I Clinical Development 479
Table 24: The Competition Through Close Mechanistic Approximation Between Phase I Melanoma Drugs 481
Table 25: First-in-Class and Me-too of Melanoma Drugs in Preclinical Development 483
Table 26: The Competition Through Close Mechanistic Approximation Between Preclinical Melanoma Drugs 484
Table 27: Target Strategies of No Data, Suspended or Terminated Melanoma Drugs 485
Table 28: Finding Competitive Profile for Best-in-Class Consideration 488
Table 29: Overview of Compound Strategy Competition Among Melanoma Drugs 680
Table 30: Overview of the Competitive Landscape of Small Molecule Based Melanoma Drugs 682
Table 31: Competitive Comparison of Target Strategies of Small Molecule Based Melanoma Drugs 683
Table 32: Pursued Target Strategies of Small Molecule Drugs Based Melanoma Drugs 686
Table 33: Overview of the Competitive Landscape of Peptide Based Melanoma Drugs 692
Table 34: Competitive Comparison of Target Strategies of Peptide Based Melanoma Drugs 693
Table 35: Pursued Target Strategies of Peptide Based Melanoma Drugs 694
Table 36: Overview of the Competitive Landscape of Protein Based Melanoma Drugs 695
Table 37: Competitive Comparison of Target Strategies of Protein Based Melanoma Drugs 696
Table 38: Pursued Target Strategies of Protein Based Melanoma Drugs 697
Table 39: Overview of the Competitive Landscape of Antibody Based Melanoma Drugs 698
Table 40: Competitive Comparison of Target Strategies of Antibody Based Melanoma Drugs 699
Table 41: Pursued Target Strategies of Antibody Based Melanoma Drugs 700
Table 42: Overview of the Competitive Landscape of Nucleic Acid Based Melanoma Drugs 702
Table 43: Competitive Comparison of Target Strategies of Nucleic Acid Based Melanoma Drugs 703
Table 44: Pursued Target Strategies of Nucleic Acid Based Melanoma Drugs 703
Table 45: Potential Forms of Cell Therapy 704
Table 46: Vectors in Gene Therapy 705
Table 47: Overview of the Competitive Landscape of Cell Therapy Based Melanoma Drugs 705
Table 48: Pursued Target Strategies of Cell Therapy Based Melanoma Drugs 705
Table 49: Overview of the Competitive Landscape of Gene Therapy Based Melanoma Drugs 706
Table 50: Competitive Comparison of Target Strategies of Gene Therapy Based Melanoma Drugs 707
Table 51: Pursued Target Strategies of Gene Therapy Based Melanoma Drugs 707
Table 52:Overview of the Competitive Landscape of Reformulated Melanoma Drugs 709
Table 53: Competitive Comparison of Target Strategies of Reformulated Melanoma Drugs 710
Table 54: Pursued Target Strategies of Reformulated Melanoma Drugs 710
Table 55: The Competition Through Close Mechanistic Approximation Among Melanoma Drugs 711
Table 56: Competitive Summary by Company of Melanoma Drug Development 716
Table 57: Summary Table of Corporate Changes in the Competitive Landscape of Melanoma Drug Development 720
Table 58: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 723
Table 59: Example of a Competitive Fall-Out Table (Targeting IL2RA Modified) 729
Table 60: 3SBio's Included Melanoma Drug Pipeline and Competitive Fall-Out 733
Table 61: AB Science's Included Melanoma Drug Pipeline and Competitive Fall-Out 735
Table 62: Abbott's Included Melanoma Drug Pipeline and Competitive Fall-Out 738
Table 63: AbbVie's Included Melanoma Drug Pipeline and Competitive Fall-Out 741
Table 64: Abiogen's Included Melanoma Drug Pipeline and Competitive Fall-Out 743
Table 65: Actelion's Included Melanoma Drug Pipeline and Competitive Fall-Out 745
Table 66: Adherex's Included Melanoma Drug Pipeline and Competitive Fall-Out 747
Table 67: Advanced Life Sciences' Included Melanoma Drug Pipeline and Competitive Fall-Out 749
Table 68: Agenus' Included Melanoma Drug Pipeline and Competitive Fall-Out 751
Table 69: Alnylam's Included Melanoma Drug Pipeline and Competitive Fall-Out 753
Table 70: AlphaVax's Included Melanoma Drug Pipeline and Competitive Fall-Out 755
Table 71: Ambit Biosciences' Included Melanoma Drug Pipeline and Competitive Fall-Out 761
Table 72: Amgen's Included Melanoma Drug Pipeline and Competitive Fall-Out 764
Table 73: AngioChem's Included Melanoma Drug Pipeline and Competitive Fall-Out 768
Table 74: Antisense Pharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 770
Table 75: Antisoma's Included Melanoma Drug Pipeline and Competitive Fall-Out 772
Table 76: Aphios' Included Melanoma Drug Pipeline and Competitive Fall-Out 774
Table 77: ApopLogic Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 776
Table 78: Apotex's Included Melanoma Drug Pipeline and Competitive Fall-Out 778
Table 79: Ariad's Included Melanoma Drug Pipeline and Competitive Fall-Out 780
Table 80: ArQule's Included Melanoma Drug Pipeline and Competitive Fall-Out 783
Table 81: Array BioPharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 786
Table 82: Astellas' Included Melanoma Drug Pipeline and Competitive Fall-Out 790
Table 83: Astex Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 794
Table 84: AstraZeneca's Included Melanoma Drug Pipeline and Competitive Fall-Out 798
Table 85: Attenuon's Included Melanoma Drug Pipeline and Competitive Fall-Out 801
Table 86: Bayer's Included Melanoma Drug Pipeline and Competitive Fall-Out 804
Table 87: Bio-Medisinsk Innovasjon's Included Melanoma Drug Pipeline and Competitive Fall-Out 808
Table 88: BioAlliance Pharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 810
Table 89: Biogen Idec's Included Melanoma Drug Pipeline and Competitive Fall-Out 813
Table 90: Biokine Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 815
Table 91: BioNTech's Included Melanoma Drug Pipeline and Competitive Fall-Out 817
Table 92: BioNumerik's Included Melanoma Drug Pipeline and Competitive Fall-Out 819
Table 93: BioSante's Included Melanoma Drug Pipeline and Competitive Fall-Out 822
Table 94: Biosceptre's Included Melanoma Drug Pipeline and Competitive Fall-Out 824
Table 95: Biotech Ltd's Included Melanoma Drug Pipeline and Competitive Fall-Out 827
Table 96: Biotecnol's Included Melanoma Drug Pipeline and Competitive Fall-Out 830
Table 97: BioVex's Included Melanoma Drug Pipeline and Competitive Fall-Out 832
Table 98: Boehringer Ingelheim's Included Melanoma Drug Pipeline and Competitive Fall-Out 834
Table 99: Bristol-Myers Squibb's Included Melanoma Drug Pipeline and Competitive Fall-Out 838
Table 100: Cancer Research Technology's Included Melanoma Drug Pipeline and Competitive Fall-Out 844
Table 101: CDG Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 846
Table 102: Celgene's Included Melanoma Drug Pipeline and Competitive Fall-Out 849
Table 103: Celldex Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 851
Table 104: Celtic Pharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 854
Table 105: CJ Corp's Included Melanoma Drug Pipeline and Competitive Fall-Out 857
Table 106: Clavis Pharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 859
Table 107: Cosmo Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 861
Table 108: CSL's Included Melanoma Drug Pipeline and Competitive Fall-Out 863
Table 109: CureTech's Included Melanoma Drug Pipeline and Competitive Fall-Out 865
Table 110: CytImmune Sciences' Included Melanoma Drug Pipeline and Competitive Fall-Out 867
Table 111: Cytokinetics' Included Melanoma Drug Pipeline and Competitive Fall-Out 869
Table 112: Daewoong's Included Melanoma Drug Pipeline and Competitive Fall-Out 871
Table 113: Daiichi Sankyo's Included Melanoma Drug Pipeline and Competitive Fall-Out 874
Table 114: Dara Biosciences' Included Melanoma Drug Pipeline and Competitive Fall-Out 878
Table 115: Deciphera Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 880
Table 116: DNAVEC's Included Melanoma Drug Pipeline and Competitive Fall-Out 883
Table 117: Dong-A's Included Melanoma Drug Pipeline and Competitive Fall-Out 886
Table 118: Eisai's Included Melanoma Drug Pipeline and Competitive Fall-Out 890
Table 119: Eli Lilly's Included Melanoma Drug Pipeline and Competitive Fall-Out 895
Table 120: EntreMed's Included Melanoma Drug Pipeline and Competitive Fall-Out 900
Table 121: Enzon's Included Melanoma Drug Pipeline and Competitive Fall-Out 904
Table 122: EpiCept's Included Melanoma Drug Pipeline and Competitive Fall-Out 907
Table 123: Exelixis' Included Melanoma Drug Pipeline and Competitive Fall-Out 911
Table 124: Flamel Technologies' Included Melanoma Drug Pipeline and Competitive Fall-Out 916
Table 125: Genmab's Included Melanoma Drug Pipeline and Competitive Fall-Out 918
Table 126: Genta's Included Melanoma Drug Pipeline and Competitive Fall-Out 920
Table 127: GenVec's Included Melanoma Drug Pipeline and Competitive Fall-Out 922
Table 128: Geron's Included Melanoma Drug Pipeline and Competitive Fall-Out 924
Table 129: GlaxoSmithKline's Included Melanoma Drug Pipeline and Competitive Fall-Out 927
Table 130: Gradalis' Included Melanoma Drug Pipeline and Competitive Fall-Out 931
Table 131: Hemispherx Biopharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 933
Table 132: Hoffmann-La Roche's Included Melanoma Drug Pipeline and Competitive Fall-Out 937
Table 133: Ichor Medical Systems' Included Melanoma Drug Pipeline and Competitive Fall-Out 944
Table 134: Idera Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 946
Table 135: Immunocore's Included Melanoma Drug Pipeline and Competitive Fall-Out 949
Table 136: ImmunoGen's Included Melanoma Drug Pipeline and Competitive Fall-Out 952
Table 137: Immunovaccine's Included Melanoma Drug Pipeline and Competitive Fall-Out 954
Table 138: ImmuPharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 956
Table 139: Incyte Corporation's Included Melanoma Drug Pipeline and Competitive Fall-Out 958
Table 140: Infinity Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 961
Table 141: Innate Pharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 963
Table 142: Inotek's Included Melanoma Drug Pipeline and Competitive Fall-Out 965
Table 143: Inovio's Included Melanoma Drug Pipeline and Competitive Fall-Out 968
Table 144: Intas Biopharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 971
Table 145: Intracel's Included Melanoma Drug Pipeline and Competitive Fall-Out 973
Table 146: Intrexon's Included Melanoma Drug Pipeline and Competitive Fall-Out 975
Table 147: Introgen Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 977
Table 148: Ipsen's Included Melanoma Drug Pipeline and Competitive Fall-Out 979
Table 149: Jennerex Biotherapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 981
Table 150: Johnson and Johnson's Included Melanoma Drug Pipeline and Competitive Fall-Out 983
Table 151: KAEL-GemVax's Included Melanoma Drug Pipeline and Competitive Fall-Out 986
Table 152: Kalypsys' Included Melanoma Drug Pipeline and Competitive Fall-Out 989
Table 153: Karyon-CTT's Included Melanoma Drug Pipeline and Competitive Fall-Out 991
Table 154: Kiadis' Included Melanoma Drug Pipeline and Competitive Fall-Out 993
Table 155: Leo's Included Melanoma Drug Pipeline and Competitive Fall-Out 995
Table 156: LG Life Sciences' Included Melanoma Drug Pipeline and Competitive Fall-Out 998
Table 157: Ligand's Included Melanoma Drug Pipeline and Competitive Fall-Out 1000
Table 158: Lipotek's Included Melanoma Drug Pipeline and Competitive Fall-Out 1002
Table 159: Mannkind's Included Melanoma Drug Pipeline and Competitive Fall-Out 1004
Table 160: Meda's Included Melanoma Drug Pipeline and Competitive Fall-Out 1006
Table 161: MediGene's Included Melanoma Drug Pipeline and Competitive Fall-Out 1009
Table 162: Medisyn Technologies' Included Melanoma Drug Pipeline and Competitive Fall-Out 1012
Table 163: Merck and Co's Included Melanoma Drug Pipeline and Competitive Fall-Out 1015
Table 164: Merck KGaA's Included Melanoma Drug Pipeline and Competitive Fall-Out 1018
Table 165: Mitsubishi Tanabe Pharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 1020
Table 166: Mochida's Included Melanoma Drug Pipeline and Competitive Fall-Out 1023
Table 167: Mojave Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 1025
Table 168: MolMed's Included Melanoma Drug Pipeline and Competitive Fall-Out 1027
Table 169: Mologen's Included Melanoma Drug Pipeline and Competitive Fall-Out 1029
Table 170: Nereus Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1031
Table 171: Non-industrial source's Included Melanoma Drug Pipeline and Competitive Fall-Out 1033
Table 172: Novartis' Included Melanoma Drug Pipeline and Competitive Fall-Out 1037
Table 173: Novogen's Included Melanoma Drug Pipeline and Competitive Fall-Out 1045
Table 174: Oasmia's Included Melanoma Drug Pipeline and Competitive Fall-Out 1048
Table 175: Oncalis' Included Melanoma Drug Pipeline and Competitive Fall-Out 1050
Table 176: Oncovir's Included Melanoma Drug Pipeline and Competitive Fall-Out 1052
Table 177: Oxford BioMedica's Included Melanoma Drug Pipeline and Competitive Fall-Out 1054
Table 178: Pacific Biotech's Included Melanoma Drug Pipeline and Competitive Fall-Out 1056
Table 179: Patrys' Included Melanoma Drug Pipeline and Competitive Fall-Out 1058
Table 180: PBL Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 1061
Table 181: Pfizer's Included Melanoma Drug Pipeline and Competitive Fall-Out 1064
Table 182: PharmaMar's Included Melanoma Drug Pipeline and Competitive Fall-Out 1070
Table 183: PhiloGene's Included Melanoma Drug Pipeline and Competitive Fall-Out 1073
Table 184: Pierre Fabre's Included Melanoma Drug Pipeline and Competitive Fall-Out 1076
Table 185: Piramal's Included Melanoma Drug Pipeline and Competitive Fall-Out 1078
Table 186: Progen's Included Melanoma Drug Pipeline and Competitive Fall-Out 1080
Table 187: Reata Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1082
Table 188: Regulon's Included Melanoma Drug Pipeline and Competitive Fall-Out 1084
Table 189: Reliance Life Sciences' Included Melanoma Drug Pipeline and Competitive Fall-Out 1087
Table 190: Rexahn's Included Melanoma Drug Pipeline and Competitive Fall-Out 1089
Table 191: Sanofi's Included Melanoma Drug Pipeline and Competitive Fall-Out 1092
Table 192: Santaris Pharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 1095
Table 193: Santhera Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1098
Table 194: Sareum's Included Melanoma Drug Pipeline and Competitive Fall-Out 1101
Table 195: Scancell's Included Melanoma Drug Pipeline and Competitive Fall-Out 1103
Table 196: Seattle Genetics' Included Melanoma Drug Pipeline and Competitive Fall-Out 1105
Table 197: Shire's Included Melanoma Drug Pipeline and Competitive Fall-Out 1107
Table 198: Simcere Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1109
Table 199: Solbec Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1111
Table 200: Spirogen's Included Melanoma Drug Pipeline and Competitive Fall-Out 1113
Table 201: Sunesis' Included Melanoma Drug Pipeline and Competitive Fall-Out 1115
Table 202: Swedish Orphan Biovitrum's Included Melanoma Drug Pipeline and Competitive Fall-Out 1118
Table 203: Synta Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1121
Table 204: Takeda's Included Melanoma Drug Pipeline and Competitive Fall-Out 1124
Table 205: Tapestry Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1128
Table 206: Targa Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 1130
Table 207: Targepeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 1132
Table 208: Tau Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 1134
Table 209: Thallion Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1136
Table 210: Therion Biologics' Included Melanoma Drug Pipeline and Competitive Fall-Out 1138
Table 211: to-BBB's Included Melanoma Drug Pipeline and Competitive Fall-Out 1140
Table 212: Tolerx's Included Melanoma Drug Pipeline and Competitive Fall-Out 1142
Table 213: TopoTarget's Included Melanoma Drug Pipeline and Competitive Fall-Out 1144
Table 214: Tracon Pharmaceuticals' Included Melanoma Drug Pipeline and Competitive Fall-Out 1146
Table 215: Transgene's Included Melanoma Drug Pipeline and Competitive Fall-Out 1148
Table 216: VBL Therapeutics' Included Melanoma Drug Pipeline and Competitive Fall-Out 1150
Table 217: Vectura's Included Melanoma Drug Pipeline and Competitive Fall-Out 1152
Table 218: Vical's Included Melanoma Drug Pipeline and Competitive Fall-Out 1155
Table 219: VioQuest's Included Melanoma Drug Pipeline and Competitive Fall-Out 1158
Table 220: WntResearch's Included Melanoma Drug Pipeline and Competitive Fall-Out 1160
Table 221: Xerion's Included Melanoma Drug Pipeline and Competitive Fall-Out 1163
Table 222: York Pharma's Included Melanoma Drug Pipeline and Competitive Fall-Out 1165

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Tumor Ablation Market by Technology, Mode of Treatment, Application - Global Forecast 2021

Tumor Ablation Market by Technology, Mode of Treatment, Application - Global Forecast 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global tumor ablation market is estimated to register a high CAGR of 12.5% during 2016-2021, and is expected to be valued at ~USD 580.1 million in 2021. Although mature markets (North America and Europe) ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.